Kim Maplestone

Kim Maplestone serves as Chief Clinical Operations Officer. She joined 4DMT in 2019 and has held various roles, most recently as SVP, Clinical Development Operations. Ms. Maplestone has demonstrated exceptional leadership and played a critical role in advancing the Company’s clinical programs, including driving the organization’s transition from early-stage to late-stage development through scalable, high-quality clinical operations.

Ms. Maplestone oversees global clinical operations for the company’s portfolio of programs, including Phase 1 through Phase 3 programs. She leads all Clinical Operations functions, and partners closely with executive leadership to support driving programs through Phase 3, and delivering inspection‑ready, high‑quality data to enable successful regulatory submissions and inspections.

Ms. Maplestone has more than two decades of experience leading global clinical development operations across gene therapy, ophthalmology, immuno-oncology, and rare diseases. Prior to joining 4DMT, Ms. Maplestone was Head of Clinical Operations at Aduro Biotech, where she led global immuno-oncology programs and served as Operations Lead for strategic alliances with Novartis, Merck, and Incyte. Earlier in her career, she held senior clinical operations and program management roles at Ultragenyx Pharmaceutical, Ipsen, Allergan, and other leading biotechnology and pharmaceutical companies.

Ms. Maplestone holds a B.A. in Business Administration from Western Washington University and has completed executive leadership training at UC Berkeley Haas School of Business and Stanford University.